Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients

Hamilton Health Sciences (HHS)

Status: Terminated

Conditions: Type 2 Diabetes

Treatments: Procedure: laparoscopic adjustable gastric banding; Procedure: Intensive Medical Management; Procedure: laparoscopic gastric bypass surgery

Study type: Interventional

Funder types: Other

Identifiers

NCT00428571

06-001

Details and patient eligibility

About

A large number of research studies on people who were morbidly obese (extremely overweight), and had bariatric surgery (anti-obesity surgery) have shown that patients who were diabetic before surgery often experienced significant improvement in their diabetes following the surgery. For some patients, blood glucose levels returned to the normal range, and they were able to stop taking all of their diabetes medications. For others, blood glucose levels improved, allowing them to reduce their diabetes medications.

This research study is being done to determine whether bariatric surgery can safely provide better control of diabetes symptoms in obese diabetics than continuing medical management (anti-diabetic drugs in combination with diet and lifestyle changes).

There are several different types of bariatric surgery currently being used to treat morbid obesity. Two of the most common techniques are gastric bypass and adjustable gastric banding. This study will be comparing these two surgical techniques to treatment with a combination of drugs, diet, and lifestyle changes for control of type 2 diabetes.

Enrollment: 20 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Residents of Southern Ontario, Canada

• Obese (BMI 30 to < 40 kg/m2) patients who have had type 2 diabetes mellitus for more than 5 years, complicated by at least one of the following situations that persist despite adequate management efforts. The complicating situations are:

  • Severely reduced quality of life as assessed by the Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire
  • Metabolic lability/instability, characterized by two or more episodes of severe hypoglycemia (≤ 3mmol/L) or severe hyperglycemia (≥ 25 mmol/L), or two or more hospital visits for diabetic complications over the last year

• Despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by:

  • Retinopathy - a minimum of a three step progression using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading system, or an equivalent progression as certified by an ophthalmologist familiar with diabetic retinopathy or
  • Nephropathy - persistent or progressive macroalbuminuria (>20 mg albumin/mmol creatinine) over at least 12 months (beginning anytime within the past two years) despite the use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) or
  • Neuropathy - persistent or progressing autonomic neuropathy (gastroparesis, postural hypotension, neuropathic bowel or bladder) or persistent or progressing severe peripheral painful neuropathy not responding to usual management (e.g., tricyclics, gabapentin, or carbamazepine)

Exclusion criteria

• Less than 18 years of age or greater than 65 years of age

• Unable to complete self and interviewer administered questionnaires in English

• Incapable of providing informed consent

• Any of the following medical conditions that may be associated with DM:

  • Recent positive history of myocardial infarction or coronary artery bypass graft or percutaneous transluminal angioplasty (less than 6 months)
  • Unstable angina pectoris
  • Recent clinically important ST-T changes on electrocardiogram (ECG) over the past year
  • Cardiac heart failure (New York Heart Association class III and IV; ejection fraction < 50%)
  • Frequent and persistent and unstable supra and ventricular arrhythmias,
  • Brain stroke, transient ischemic attack (TIA),
  • Major diabetic foot infections
  • Autonomic neuropathy resulting in orthostatic dysregulation

• History of any psychiatric illness that would make the patient a poor candidate for bariatric surgery, as determined by the study psychiatrist

• If female, pregnant or planning to become pregnant within next year

• Clinically important cancer history (impact on either lifespan or performance of lap. bariatric surgery)

• Clinically important abdominal or thoracic surgery that would impact the performance of laparoscopic bariatric procedure

• Insulin dependence for more than 10 years

• American Society of Anesthesiologists' classification of 4 or higher

• Severe gastrointestinal reflux disease with Grade 3 or 4 esophagitis

• History of pulmonary embolism or deep vein thrombosis

• Presently taking either high-dose steroids or anticoagulants

• Advanced nephropathy (Stage 4 or 5 - eGFR less than 30 ml/min)

• Any other condition that, in the opinion of the study surgeons, would make the patient a poor candidate for bariatric surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 3 patient groups, including a placebo group

Intensive Medical Management

Placebo Comparator group

Description:

Medical management of obesity including medication optimization and lifestyle and dietary advice.

Treatment:

Procedure: Intensive Medical Management

Laparoscopic Gastric Bypass

Active Comparator group

Treatment:

Procedure: laparoscopic gastric bypass surgery

Laparoscopic Adjustable Gastric Band

Active Comparator group

Treatment:

Procedure: laparoscopic adjustable gastric banding